Azilsartan medoxomil/chlortalidone

Drug Profile

Azilsartan medoxomil/chlortalidone

Alternative Names: Chlortalidone/azilisartan medoxomil; Edarbyclor; TAK-491/chlorthalidone; TAK-491CLD

Latest Information Update: 22 Jun 2015

Price : $50

At a glance

  • Originator Takeda
  • Class Antihypertensives; Benzimidazoles; Small molecules; Sulfonamides
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 22 Jun 2015 No recent reports on development identified - Preregistration for Hypertension in Indonesia (PO)
  • 22 Jun 2015 Launched for Hypertension in Thailand, Hong Kong, Switzerland and Taiwan (PO) before June 2015
  • 17 Dec 2014 Azilsartan medoxomil licensed to Valeant in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top